Infectious Pulmonary Diseases

Rafeq, Rachel; Igneri, Lauren

doi:10.1016/j.emc.2022.05.005

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infection with P. aeruginosa is associated with some infectious diseases, including the sepsis ( Cheluvappa et al, 2009 ; Mittal et al, 2009 ; Bassetti et al, 2018 ; Rafeq and Igneri, 2022 ). As one of the most feared nosocomial pathogens, treatment of P. aeruginosa infection is challenging due to the limited choices of antibiotics ( Ibrahim et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Treatment with paeoniflorin increases lifespan of Pseudomonas aeruginosa infected Caenorhabditis elegans by inhibiting bacterial accumulation in intestinal lumen and biofilm formation

et al. 2023

View full text Add to dashboard Cite

Paeoniflorin is one of the important components in Paeoniaceae plants. In this study, we used Caenorhabditis elegans as a model host and Pseudomonas aeruginosa as a bacterial pathogen to investigate the possible role of paeoniflorin treatment against P. aeruginosa infection in the host and the underlying mechanisms. Posttreatment with 1.25–10 mg/L paeoniflorin could significantly increase the lifespan of P. aeruginosa infected nematodes. After the infection, the P. aeruginosa colony-forming unit (CFU) and P. aeruginosa accumulation in intestinal lumen were also obviously reduced by 1.25–10 mg/L paeoniflorin treatment. The beneficial effects of paeoniflorin treatment in increasing lifespan in P. aeruginosa infected nematodes and in reducing P. aeruginosa accumulation in intestinal lumen could be inhibited by RNAi of pmk-1, egl-1, and bar-1. In addition, paeoniflorin treatment suppressed the inhibition in expressions of pmk-1, egl-1, and bar-1 caused by P. aeruginosa infection in nematodes, suggesting that paeoniflorin could increase lifespan of P. aeruginosa infected nematode by activating PMK-1, EGL-1, and BAR-1. Moreover, although treatment with 1.25–10 mg/L paeoniflorin did not show obvious anti-P. aeruginosa activity, the P. aeruginosa biofilm formation and expressions of related virulence genes (pelA, pelB, phzA, lasB, lasR, rhlA, and rhlC) were significantly inhibited by paeoniflorin treatment. Treatment with 1.25–10 mg/L paeoniflorin could further decrease the levels of related virulence factors of pyocyanin, elastase, and rhamnolipid. In addition, 2.5–10 mg/L paeoniflorin treatment could inhibit the swimming, swarming, and twitching motility of P. aeruginosa, and treatment with 2.5–10 mg/L paeoniflorin reduced the cyclic-di-GMP (c-di-GMP) level. Therefore, paeoniflorin treatment has the potential to extend lifespan of P. aeruginosa infected hosts by reducing bacterial accumulation in intestinal lumen and inhibiting bacterial biofilm formation.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with paeoniflorin increases lifespan of Pseudomonas aeruginosa infected Caenorhabditis elegans by inhibiting bacterial accumulation in intestinal lumen and biofilm formation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Other immunocompromising factors which may account for increased risk of infection associated with SGA use have been proposed. Off‐target effects of SGAs at the thromboxane A2 receptor (TBXA2R) and platelet‐activating factor receptor (PTAFR) have been implicated in increased pneumonia prevalence, 20 as TBXA2R and PTAFR mediate capillary permeability at the alveolar level, which if compromised can lead to alveoli oedema–a recognised risk factor as well as symptom of pneumonia 21 . There is also emerging evidence to suggest that clozapine can impede immunoglobulin function 22–26 …”

Section: Introductionmentioning

confidence: 99%

“…Off-target effects of SGAs at the thromboxane A2 receptor (TBXA2R) and plateletactivating factor receptor (PTAFR) have been implicated in increased pneumonia prevalence, 20 as TBXA2R and PTAFR mediate capillary permeability at the alveolar level, which if compromised can lead to alveoli oedema-a recognised risk factor as well as symptom of pneumonia. 21 There is also emerging evidence to suggest that clozapine can impede immunoglobulin function. [22][23][24][25][26] Few studies have examined risk differences between individual antipsychotics 23,24,27 or association with pneumonia-related death.…”

Section: Introductionmentioning

confidence: 99%

“…[22][23][24][25][26] Few studies have examined risk differences between individual antipsychotics 23,24,27 or association with pneumonia-related death. In this study, we have examined the association of specific antipsychotic exposure to overall pneumonia-related mortality, and performed sub-analysis by pneumonia type-pneumonia can manifest due to pathogenic infection or aspiration of substances, 21 and it is important to understand if there is differential risk with antipsychotic use between pneumonia types.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case–control study of antipsychotic use and pneumonia‐related mortality in the United Kingdom

Copeland

Wallman

Morgan

et al. 2023

Acta Psychiatr Scand

View full text Add to dashboard Cite

Background and aim There is increasing evidence linking antipsychotic use with pneumonia, but limited evidence of an effect on pneumonia‐related outcomes such as mortality. In this study, we aimed to examine the association of pneumonia‐related death with specific antipsychotic exposure. Method Deaths analysed were those reported to a UK‐based drug‐related deaths database, the National Programme on Substance Abuse Deaths (NPSAD), between 1997 and September 2020. We conducted a case–control study with cases defined as pneumonia‐related deaths and controls as cases with alternative causes of death. Cases were analysed by considering drugs detected at post‐mortem (PM) and by drugs prescribed to the deceased at the time of their death with calculated odds ratios (ORs) adjusted to account for confounders. Results There were 2467 PM cases and 40,128 controls; 1818 prescribed cases and 28,018 controls. Second generation antipsychotics (SGAs) were robustly associated with an increased risk of pneumonia‐related death compared with those not prescribed or taking antipsychotics (PM detection adjusted OR [AOR] 1·34 [95% CI 1·15–1·55]; prescribed AOR 1·28 [95% CI 1·11–1·49]). First generation antipsychotics had no clear association with death from pneumonia (PM detection AOR 1·06 [95% CI 0·77–1·47]; prescribed AOR 0·91 [95% CI 0·71–1·17]). Amongst SGAs, olanzapine was associated with an increased risk of death due to pneumonia (PM detection AOR 1·49 [95% CI 1·22–1·82]; prescribed AOR 1·44 [95% CI 1·18–1·76]) as was quetiapine (PM detection AOR 1·34 [95% CI 1·07–1·66]; prescribed AOR 1·28 [95% CI 1·01–1·64]). Conclusion Olanzapine and quetiapine were found to increase the risk of pneumonia‐related death in this NPSAD sample to a clinically important extent.

show abstract

Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects

Nadaf,

Kumbhar,

Bhagwat

et al. 2024

Smart Nanomaterials for Infectious Diseases

View full text Add to dashboard Cite

Increased respiratory tract infections have placed a socioeconomic load on the global healthcare system, particularly in developing nations. The lack of alternative therapeutic options has seriously threatened the health of many populations. With the use of passive, active, or physicochemical targeting techniques, nanomedicine-based delivery systems have been developed to enhance the biopharmacokinetic properties and therapeutic results of drugs effective against lung infections. Owing to their physicochemical properties, controlled in vivo behaviour, and the ability for multimodal imaging, NPs are the preferred contrast agents. This chapter provides an overview of respiratory infections and illuminates several barriers of bacterial infections. The features and benefits of nanosized materials for diagnosing various lung diseases are analysed. The current trends of different nanosystems such as lipid-based vesicles, including solid lipid NPs, nanostructured lipid carriers, polymeric micelles, dendrimers, etc., for treating several life-threatening lung infections, including COVID-19, are reviewed and discussed, highlighting their benefits and limitations. The current state of nanovaccines for treating lung infections is highlighted in a separate section. The challenges and prospects of nanostrategies for treating lung infections are considered in the last section.

show abstract

Infectious Pulmonary Diseases

Cited by 3 publications

References 29 publications

Treatment with paeoniflorin increases lifespan of Pseudomonas aeruginosa infected Caenorhabditis elegans by inhibiting bacterial accumulation in intestinal lumen and biofilm formation

Treatment with paeoniflorin increases lifespan of Pseudomonas aeruginosa infected Caenorhabditis elegans by inhibiting bacterial accumulation in intestinal lumen and biofilm formation

A case–control study of antipsychotic use and pneumonia‐related mortality in the United Kingdom

Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects

Contact Info

Product

Resources

About